Jeff P. Sharman

Willamette Valley Cancer Institute and Research Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 7 papers. Top paper: “Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia”.

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

New England Journal of Medicine(2013)10.1056/nejmoa1215637

N/A

18.9DataRank · unranked

2265 citations

Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan A. Burger, Kristie A. Blum +16 more

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-2856

N/A

4.5DataRank · unranked

184 citations

Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum +9 more

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood(2025)10.1182/blood.2024024476

N/A

0.710DataRank · unranked

42 citations

Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, Krish Patel, Ian W. Flinn +22 more

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology(2025)10.1200/jco-25-00925

N/A

0.520DataRank · unranked

31 citations

Gilles Salles, Laurie H. Sehn, Alex F. Herrera, Jonathan W. Friedberg, Marek Trněný +32 more

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials

Blood Advances(2024)10.1182/bloodadvances.2023011307

N/A

0.442DataRank · unranked

18 citations

Jeff P. Sharman, Paolo Ghia, Jennifer A. Woyach, Toby A. Eyre, Wojciech Jurczak +7 more

No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib

Leukemia & lymphoma/Leukemia and lymphoma(2020)10.1080/10428194.2020.1845339

N/A

0.200DataRank · unranked

2 citations

Peter Hillmen, Gilles Salles, Jeff P. Sharman, Stephan Stilgenbauer, Oksana Gurtovaya +6 more

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3261

N/A

0DataRank · unranked

30 citations

Manish R. Patel, John M. Burke, Ranjana H. Advani, Bruce D. Cheson, Jeff P. Sharman +11 more